Enlivex Therapeutics Closes Private Placement
Ticker: ENLV · Form: 6-K · Filed: Nov 26, 2025 · CIK: 1596812
| Field | Detail |
|---|---|
| Company | Enlivex Therapeutics Ltd. (ENLV) |
| Form Type | 6-K |
| Filed Date | Nov 26, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $1.00, $0.99, $212.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, private-placement, company-update
Related Tickers: ENLV
TL;DR
ENLV closed its private placement on Nov 24, 2025. Capital raised.
AI Summary
Enlivex Therapeutics Ltd. announced the closing of its previously reported private placement on November 24, 2025. The company, organized under the laws of Israel, completed this financing round.
Why It Matters
The closing of a private placement indicates the company has successfully raised capital, which can be used for operations, research, or expansion.
Risk Assessment
Risk Level: medium — Private placements can be complex and involve risks related to dilution and the terms of the agreement.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- November 24, 2025 (date) — Closing date of private placement
- Israel (location) — Company's place of organization
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K filing is to report the closing of a previously announced private placement by Enlivex Therapeutics Ltd.
When did Enlivex Therapeutics Ltd. close its private placement?
Enlivex Therapeutics Ltd. closed its private placement on November 24, 2025.
Under which jurisdiction is Enlivex Therapeutics Ltd. organized?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
What was the previous name of Enlivex Therapeutics Ltd.?
The company was formerly known as Bioblast Pharma Ltd., with a name change in 2016 and prior to that, BIO BLAST PHARMA LTD. with a name change in 2014.
What is the principal executive office address of Enlivex Therapeutics Ltd.?
The principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel 7403618.
Filing Stats: 976 words · 4 min read · ~3 pages · Grade level 13.6 · Accepted 2025-11-26 08:03:15
Key Financial Figures
- $1.00 — urities ”) at a purchase price of $1.00 per Share or $0.99 per Pre-Funded Warra
- $0.99 — a purchase price of $1.00 per Share or $0.99 per Pre-Funded Warrant in lieu thereof
- $212.0 million — rchasers ”). The Company received $212.0 million in gross proceeds from the Private Plac
Filing Documents
- ea0267296-6k_enlivex.htm (6-K) — 18KB
- ea026729601ex99-1_enlivex.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-25-115075.txt ( ) — 42KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: November 26, 2025 3